On Monday, BofA Securities adjusted its outlook on Owens & Minor (NYSE:OMI), a healthcare logistics company, reducing the price target to $12.50 from the previous $15.50. The firm maintained its Underperform rating on the stock. This revision follows Owens & Minor's recent earnings report, which delivered a mixed performance for the quarter.
Owens & Minor experienced robust EBIT growth within its Patient Direct segment, which was a positive takeaway from the quarter. The company attributed this success to factors including fixed cost leverage and accelerated patient onboarding. However, the Products & Health Services segment did not perform as well, presenting challenges that BofA Securities believes cannot be easily dismissed.
The company's lowered gross margin guidance, particularly related to the Products & Health Services segment, raises concerns about the competitive landscape in medical distribution. BofA Securities expressed increased caution regarding the margin trajectory leading into 2025 due to these concerns.
Owens & Minor's broader efforts to turn around its performance involve a complex strategy. The company aims to reduce costs, enhance working capital efficiency, decrease debt, and invest in growth. Some progress was noted in these areas during the quarter, but the firm remains cautious.
The revised price objective is based on approximately 4.5 times the estimated CY25E EV/EBITDA, a decrease from the prior multiple of 5.5 times CY24E. The reduction reflects the challenges faced by Owens & Minor in the medical distribution sector, despite the strength observed in the Patient Direct segment. The ongoing financial leverage and the dimmer outlook for medical distribution were key factors influencing BofA Securities' decision.
In other recent news, Owens & Minor reported noteworthy Q3 earnings that surpassed analyst expectations, backed by a 5% YoY revenue growth. The company's earnings per share stood at $0.42, outperforming the predicted $0.41, and revenue was reported at $2.72 billion, exceeding the $2.68 billion estimates. These results were largely propelled by robust demand in its Patient Direct and Medical Distribution segments.
The Patient Direct segment saw a 6% increase in revenue to $687 million, primarily due to strength in diabetes and sleep supplies. The Products & Healthcare Services (NASDAQ:HCSG) segment also experienced a 5% revenue growth to $2.0 billion, largely driven by strong same-store sales in Medical Distribution.
Despite these positive results, the company reported a GAAP net loss of $13 million for the quarter. However, adjusted EBITDA saw a 5% YoY increase to $142 million. Furthermore, Owens & Minor managed to reduce its total debt by $198 million in Q3, including the full redemption of its 2024 senior notes.
Looking ahead, the company has adjusted its full-year 2024 guidance, now projecting an EPS between $1.45 and $1.55, and revenue in the range of $10.6 billion to $10.8 billion. These recent developments provide a snapshot into the company's recent performance and future expectations.
InvestingPro Insights
To complement BofA Securities' analysis of Owens & Minor (NYSE:OMI), recent data from InvestingPro offers additional perspective on the company's financial position and market valuation. Despite the challenges highlighted in the article, InvestingPro Tips suggest that OMI's net income is expected to grow this year, and the company's valuation implies a strong free cash flow yield. These factors could potentially offset some of the concerns raised about the Products & Health Services segment's performance.
InvestingPro data shows that OMI's revenue for the last twelve months as of Q2 2024 stood at $10.53 billion, with a revenue growth of 3.92% over the same period. This aligns with the article's mention of mixed performance, as the company is still showing growth despite facing headwinds. The company's adjusted P/E ratio of 7.84 suggests that the stock may be undervalued relative to its earnings potential, which could be of interest to value-oriented investors.
It's worth noting that OMI's market capitalization is currently $986.83 million, reflecting the market's current assessment of the company's value in light of recent performance and future expectations. For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide further insights into OMI's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.